# Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO, And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population.

> **NCT02826005** · NA · UNKNOWN · sponsor: **Ilex Medical** · enrollment: 400 (estimated)

## Conditions studied

- Fibrosis

## Interventions

- **DEVICE:** MRI

## Key facts

- **NCT ID:** NCT02826005
- **Lead sponsor:** Ilex Medical
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2016-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02826005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02826005, "Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO, And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02826005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*